| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/15/2010 | CA2749394A1 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections |
| 07/15/2010 | CA2749261A1 Combination therapies for neoplastic disorders |
| 07/15/2010 | CA2749228A1 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| 07/15/2010 | CA2749174A1 Benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses |
| 07/15/2010 | CA2749099A1 Method for treating hyperglycemia with glp-1 |
| 07/15/2010 | CA2749084A1 Method of treating neuropathic pain |
| 07/15/2010 | CA2749034A1 Treatment of soft tissue injury using hyaluronic acid and botulinum toxin |
| 07/15/2010 | CA2749015A1 Pyridazinone derivatives |
| 07/15/2010 | CA2749012A1 Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
| 07/15/2010 | CA2749009A1 Method for improved bioactivation of pharmaceuticals |
| 07/15/2010 | CA2748911A1 Pyridazinone derivatives |
| 07/15/2010 | CA2748908A1 Benzothiazolone derivatives |
| 07/15/2010 | CA2748843A1 Heterotricyclic compounds as positive allosteric modulators of metabotropic glutamate receptors |
| 07/15/2010 | CA2748827A1 Composition and method for treatment of diabetes |
| 07/15/2010 | CA2748814A1 Methods for treating vascular leak syndrome |
| 07/15/2010 | CA2748813A1 Pro-neurogenic compounds |
| 07/15/2010 | CA2748792A1 Combination of a cyclosporine derivative and nucleosides for treating hcv |
| 07/15/2010 | CA2748181A1 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| 07/15/2010 | CA2747670A1 Carbazole carboxamide compounds useful as kinase inhibitors |
| 07/15/2010 | CA2747662A1 Sulfonamides as trpm8 modulators |
| 07/15/2010 | CA2747658A1 Method for treating inflammatory conditions |
| 07/15/2010 | CA2747637A1 Sulfamides as trpm8 modulators |
| 07/15/2010 | CA2747636A1 Hcv ns3 protease inhibitors |
| 07/15/2010 | CA2747564A1 Combined disinfection and decontamination agent with elevated effectiveness |
| 07/15/2010 | CA2747558A1 New salts |
| 07/15/2010 | CA2747478A1 Method for treating macular degeneration |
| 07/15/2010 | CA2747437A1 Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid |
| 07/15/2010 | CA2747417A1 Compounds for the prevention and treatment of cardiovascular disease |
| 07/15/2010 | CA2747411A1 Phenylephrine formulations with improved stability |
| 07/15/2010 | CA2747161A1 Compounds and methods of use |
| 07/15/2010 | CA2747154A1 Immunocytokines for tumour therapy with chemotherapeutic agents |
| 07/15/2010 | CA2747013A1 Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| 07/15/2010 | CA2746943A1 Serotonin 5-ht2b receptor inhibitors |
| 07/15/2010 | CA2746855A1 Extended-release pharmaceutical formulations |
| 07/15/2010 | CA2746762A1 Gpr120 receptor agonists and uses thereof |
| 07/15/2010 | CA2746746A1 Arylcyclopropylacetamide derivatives useful as glucokinase activators |
| 07/15/2010 | CA2746740A1 Purine compounds |
| 07/15/2010 | CA2746509A1 Method of treatment of aggression |
| 07/15/2010 | CA2746508A1 Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| 07/15/2010 | CA2745085A1 Tricyclic azaindoles |
| 07/15/2010 | CA2745039A1 Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor |
| 07/15/2010 | CA2744266A1 Steroidal compositions |
| 07/15/2010 | CA2744231A1 Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol |
| 07/14/2010 | EP2206785A1 Improved expression of HIV polypeptides and production of virus-like particles |
| 07/14/2010 | EP2206781A2 Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| 07/14/2010 | EP2206727A1 ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15 |
| 07/14/2010 | EP2206719A2 Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor |
| 07/14/2010 | EP2206715A1 Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor |
| 07/14/2010 | EP2206714A1 Agent for prevention and/or treatment of skin diseases |
| 07/14/2010 | EP2206713A1 Beta-carbolines useful for treating inflammatory disease |
| 07/14/2010 | EP2206712A1 "Alkaloid aminoester derivatives and medicinal composition thereof" |
| 07/14/2010 | EP2206711A2 Tetomilast polymorphs |
| 07/14/2010 | EP2206710A1 Indole derivatives as S1P1 receptor agonists |
| 07/14/2010 | EP2206709A2 Thiophene derivatives as antiviral agents for flavivirus infection |
| 07/14/2010 | EP2206707A1 Azolecarboxamide compound or salt thereof |
| 07/14/2010 | EP2206704A1 Pharmaceutically active diazepanes |
| 07/14/2010 | EP2206702A1 Bicyclic compound, production and use thereof |
| 07/14/2010 | EP2206701A1 Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester) |
| 07/14/2010 | EP2206700A1 Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester) |
| 07/14/2010 | EP2206699A1 Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester) |
| 07/14/2010 | EP2206698A1 Ethynylindole compounds |
| 07/14/2010 | EP2206534A1 Dibenzocycloheptanone derivatives und pharmaceutical agents containing these compounds |
| 07/14/2010 | EP2206533A2 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene hydrazino -2'-hydroxy- 1,1'-biphenyl -3-carboxylic acid bis-(monoethanolamine) |
| 07/14/2010 | EP2206518A1 Pharmaceutical composition containing lipophilic il-2 production inhibitor |
| 07/14/2010 | EP2206517A1 Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| 07/14/2010 | EP2206512A2 Increase of interferon-beta for anti-virus therapy for respiratory diseases |
| 07/14/2010 | EP2206509A1 Aloe vera extract, method of producing aloe vera extract, and hyperglycemia improving agent |
| 07/14/2010 | EP2206506A1 Probiotic formulations |
| 07/14/2010 | EP2206504A1 Stable bicarbonate ion-containing drug solution |
| 07/14/2010 | EP2206502A1 Polymer conjugate of steroid |
| 07/14/2010 | EP2206501A2 HMGA binding nucleic acids |
| 07/14/2010 | EP2206500A1 A solid pharmaceutical dosage formulation comprising lopinavir |
| 07/14/2010 | EP2206499A1 Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists |
| 07/14/2010 | EP2206498A1 Mixed ORL1/[mu] agonists for treating pain |
| 07/14/2010 | EP2206497A1 Polymorphic form of atorvastatin calcium |
| 07/14/2010 | EP2206496A1 Medical use of inhibitors of glutaminyl and glutamate cyclases |
| 07/14/2010 | EP2206494A1 Foamable suspension gel |
| 07/14/2010 | EP2205750A1 Controlled activation of non-ltr retrotransposons in mammals |
| 07/14/2010 | EP2205746A2 Modulating gene expression with agrna and gapmers targeting antisense transcripts |
| 07/14/2010 | EP2205741A2 Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
| 07/14/2010 | EP2205620A2 An amorphous form of an anti-inflammatory compound |
| 07/14/2010 | EP2205616A1 Novel sulfated oligosaccharide derivatives |
| 07/14/2010 | EP2205610A1 Thienopyrimidiene derivatives as pi3k inhibitors |
| 07/14/2010 | EP2205607A1 Thienopyrimidine compounds |
| 07/14/2010 | EP2205605A1 Hydrated crystalline esters of camptothecin for the treatment of cancer |
| 07/14/2010 | EP2205604A1 {[5-(phenyl)-6-phenylpyrrolo[2,1-f][2,1,4]triazin-4-yl]amino}carboxylic acid derivatives and related compounds as prostacyclin (pgi2) ip receptor activators for treating cardiovascular disorders |
| 07/14/2010 | EP2205603A1 Pyrimidine derivatives as protein kinase inhibitors |
| 07/14/2010 | EP2205601A1 Purine derivatives as adenosine al receptor ligands |
| 07/14/2010 | EP2205600A1 CARBACEPHEM ß -LACTAM ANTIBIOTICS |
| 07/14/2010 | EP2205599A1 Cgrp antagonists |
| 07/14/2010 | EP2205598A1 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 07/14/2010 | EP2205596A1 (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
| 07/14/2010 | EP2205595A1 Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors |
| 07/14/2010 | EP2205594A1 1,3,5-trisubstituted triazole derivative |
| 07/14/2010 | EP2205593A1 Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof |
| 07/14/2010 | EP2205592A1 Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 07/14/2010 | EP2205591A1 Novel polymorphs of bosentan |
| 07/14/2010 | EP2205590A1 Cgrp antagonists |
| 07/14/2010 | EP2205588A2 Oxypiperidine derivatives as histamine receptor antagonists |
| 07/14/2010 | EP2205587A2 Novel compounds |